Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS)

P Lamprecht, F Moosig, S Adam-Klages, U Mrowietz, E Csernok, M Kirrstetter, K Ahmadi-Simab, J O Schroder, W L Gross

Case reports: A 66 year old female patient had relapsing fever and non-suppurative panniculitis suggestive of enigmatic “Weber-Christian disease” (WCD). Antineutrophil cytoplasmic antibodies with specificity for human leucocyte elastase (HLE-ANCA) were detected. A biopsy showed small vessel vasculitis and panniculitis. A 53 year old man had recurrent episodes of abdominal pain, erythematous rash, and myalgia. Fever attacks had stopped a few years ago. A biopsy showed panniculitis and fasciitis. In both patients mutations (R92Q, T50M) of the tumour necrosis factor receptor super family (TNFRSF) 1A gene were disclosed. Mutations of the TNFRSF 1A gene are the cause of tumour necrosis factor receptor associated periodic syndrome (TRAPS). Both patients responded favourably to treatment with the human soluble p75 TNFα receptor fusion protein etanercept (2×25 mg subcutaneously/week).

Discussion: Small vessel vasculitis and panniculitis have not been reported in TRAPS so far. The cases underline the importance of TNFα regulation in inflammatory processes including vasculitis. Genetically determined causes of fever may account for some cases of WCD.
arthralgia, myalgia, abdominal and pleuritic chest pain have manifestations such as migratory erythematous macules, fasciitis, and—as a consequence—a diminished shedding of the potentially antago-
down regulation of the membrane expressed form of the receptor, a diminished shedding of the potentially antago-
down regulation of the membrane expressed form of the receptor, a diminished shedding of the potentially antago-
down regulation of the membrane expressed form of the receptor, a diminished shedding of the potentially antago-
down regulation of the membrane expressed form of the receptor, a diminished shedding of the potentially antago-
down regulation of the membrane expressed form of the receptor, a diminished shedding of the potentially antago-
down regulation of the membrane expressed form of the receptor, a diminished shedding of the potentially antago-
down regulation of the membrane expressed form of the receptor, a diminished shedding of the potentially antago-
down regulation of the membrane expressed form of the receptor, a diminished shedding of the potentially antago-
down regulation of the membrane expressed form of the receptor, a diminished shedding of the potentially antago-

Family history was remarkable for his late father who had had abdominal pain and arthralgia. Two of his children had recurrent febrile episodes. Analysis of the TNFRSF 1A gene disclosed the T50M mutation in the patient (fig 2) and both children (data not shown). TRAPS was diagnosed. Etanercept treatment (2×25 mg subcutaneously/week) resulted in remission of the disease and successful tapering of the dose of concomitant prednisolone.

DISCUSSION
We found mutations (R92Q, T50M) in the TNFRSF 1A gene coding for the p55 TNF receptor as the underlying cause of recurrent febrile episodes and biopsy proven panniculitis in two patients. One patient also had cutaneous small vessel vasculitis. The other had fasciitis. Both patients had systemic manifestations such as oligoarthritis, migratory erythema-
tous macules, oligoarthritis, and myalgia. To our knowledge small vessel vasculitis and panniculitis have not been reported in TRAPS so far.

TRAPS is caused by mutations in the extracellular region of the p55 TNF receptor, resulting in impaired cleavage and down regulation of the membrane expressed form of the receptor, a diminished shedding of the potentially antagonistic soluble form of the receptor, and—as a consequence—unbalanced TNFα action.34 Miscellaneous clinical manifestations such as migratory erythematous macules, fasciitis, arthralgia, myalgia, abdominal and pleuritic chest pain have been reported in TRAPS.35 Our first patient also had migratory erythematous macules, but unlike the second patient no erythematous nodules typical of panniculitis. Low titre HLE-ANCA were repeatedly detected in our first patient, but the relation to TRAPS (as well as to other vasculitides) remains unclear. Interestingly, ANCA have been shown before in another hereditary disorder characterised by low major histocompatibility complex class I expression, a dysregulated immune response, and a clinical condition closely resembling Wegener’s granulomatosis.6 The second patient had fasciitis and panniculitis. Fasciitis has been reported as a manifestation of TRAPS only recently.7

Based on our findings and previous reports on dermatological and systemic manifestations,7,8 it seems likely that impaired TNFα regulation might predominantly affect the skin as well as the synovia and mesothelia—that is, highly vascularised tissues, in TRAPS. Premature leucocyte activation due to impaired TNFα regulation and consecutive endothelial damage might result in vasculitis or panniculitis, or both, in some patients with TRAPS. The observation of vasculitis in TRAPS also adds further weight to reports on a pivotal role of impaired TNFα regulation in the pathogenesis of some primary systemic vasculitides such as Wegener’s granulomatosis.8 Against this background TNFα blockade with the human soluble p75 TNFα receptor fusion protein etanercept is advocated as the preferred treatment in TRAPS.10 11

Of note, we analysed another three patients presenting with relapsing febrile non-suppurative panniculitis of unknown cause for mutations of the TNFRSF 1A gene and other causes of hereditary periodic fevers. We found no mutations in these three patients. Our report suggests that other currently unknown hereditary and environmental factors might still be disclosed as causes of “idiopathic” relapsing panniculitis and vasculitides.

Figure 2 DNA sequence electropherogram demonstrating the TNFRSF 1A gene mutation. Single nucleotide substitutions (missense mutations) in different exons result in the substitution of single amino acids in the transcribed p55 TNF receptor. Polymerase chain reaction (PCR) of exons 2–5 of the TNFRSF 1A gene was performed twice using primers as described previously.34 PCR products were purified and sequenced in both directions demonstrating the R92Q mutation in patient 1 and the T50M mutation in patient 2.
REFERENCES


Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS)

P Lamprecht, F Moosig, S Adam-Klages, U Mrowietz, E Csernok, M Kirrstetter, K Ahmadi-Simab, J O Schroder and W L Gross

Ann Rheum Dis 2004 63: 1518-1520
doi: 10.1136/ard.2003.016733

Updated information and services can be found at:
http://ard.bmj.com/content/63/11/1518

These include:

References
This article cites 11 articles, 0 of which you can access for free at:
http://ard.bmj.com/content/63/11/1518#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Vascularitis (294)
- Connective tissue disease (4253)
- Pathology (444)
- Clinical diagnostic tests (1282)
- Radiology (1113)
- Surgical diagnostic tests (431)
- Immunology (including allergy) (5144)
- Musculoskeletal syndromes (4951)
- Pain (neurology) (883)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/